Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROSPECT LUNG: Perioperative vs Adjuvant Therapy in Resectable NSCLC
NCT06632327Phase 3Active, not recruiting
- Sponsor
- Cancer and Leukemia Group B
- Start
- Dec 2024
- Primary completion
- Apr 2029
- Modality
- Immune Checkpoint Inhibitors, DNA Intercalators/Alkylators, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nivolumab, pembrolizumab and atezolizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Cancer and Leukemia Group B. Primary endpoints: Real-World Event-Free Survival at 3 years and Overall Survival at 10 years. Started Dec 2024; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06632327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06632327.